Journal
TRANSLATIONAL ANDROLOGY AND UROLOGY
Volume -, Issue -, Pages -Publisher
AME PUBLISHING COMPANY
DOI: 10.21037/tau-23-124
Keywords
Muscle invasive bladder cancer (MIBC); bladder preservation therapy; bladder-sparing; chemoradiation; trimodal therapy (TMT)
Categories
Ask authors/readers for more resources
In recent years, the use of less-invasive bladder-sparing trimodal therapy (TMT) for selected patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) has been increasing. This review summarizes the current evidence and future perspectives of bladder-sparing therapy for MIBC. Combination therapy is more effective than monotherapy, and radiotherapy alone has poorer outcomes compared to chemoradiotherapy. Appropriate patient selection and a multi-disciplinary approach are crucial for successful bladder-sparing therapy.
Background and Objective: In recent years, the application of less-invasive bladder-sparing trimodal therapy (TMT) in selected muscle-invasive bladder cancer (MIBC) patients unfit for or who declined radical cystectomy (RC) has been increasing. This review aims to summarize the current evidence and future perspectives of bladder-sparing therapy for MIBC.Methods: A non-systematic Medline/PubMed literature search was conducted on July 2022 with the following keywords 'MIBC', 'bladder-sparing', 'chemotherapy', 'radiotherapy', 'trimodal', 'multimodal', and 'immunotherapy'.Key Content and Findings: All monotherapies are inferior to RC or combination therapy and should not be routinely used for curative intent. Radiotherapy (RT) alone has been shown to have poorer outcomes when compared to chemoradiotherapy. The ideal selection criteria for TMT include good bladder function and capacity, clinical stage within cT2, complete transurethral resection of bladder tumor (TURBT), no prior history of pelvic RT, no extensive carcinoma in situ (CIS), and absence of hydronephrosis. The emergence of immunotherapy may further increase the effect of bladder-sparing therapy. Novel predictive biomarkers are awaited for more precise patient selection and better oncological outcomes.Conclusions: TMT is a well-tolerated and offers a curative alternative approach to RC for selected patients with localized MIBC. Appropriate patient selection and a multi-disciplinary approach is crucial in achieving good oncologic control with bladder-sparing therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available